Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioLASCO Taiwan CoROCO:6662 -0.17%77 EBITDA Margin % is 31.26% as of Dec. 2025, which is 28% above its 10-year median of 24.43. GuruFocus rates ROCO:6662 with a GF Score™ of 77/100 and a GF Value™ of NT$34.19 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 940 Biotechnology companies, BioLASCO Taiwan Co ranks better than 85.85% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. BioLASCO Taiwan Co's EBITDA for the
three
months ended in Dec. 2025 was NT$21.7 Mil. BioLASCO Taiwan Co's Revenue for the
three
months ended in Dec. 2025 was NT$69.3 Mil. Therefore, BioLASCO Taiwan Co's EBITDA margin for the quarter that ended in Dec. 2025 was 31.26%.
BioLASCO Taiwan Co (ROCO:6662) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
BioLASCO Taiwan Co EBITDA Margin % Related Terms
BioLASCO Taiwan Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for BioLASCO Taiwan Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6662 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, BioLASCO Taiwan Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioLASCO Taiwan Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioLASCO Taiwan Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where BioLASCO Taiwan Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioLASCO Taiwan Co (ROCO:6662) has a EBITDA Margin % of 31.26% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on BioLASCO Taiwan Co and its competitors. This is 28% above median its historical median of 24.43. Over the past decade, BioLASCO Taiwan Co's EBITDA Margin % has ranged from 21.76 to 29.73. According to the industry distribution chart, BioLASCO Taiwan Co ranks #133 out of 940 companies in the Biotechnology industry, placing it in the top 14.1%.
Is BioLASCO Taiwan Co's EBITDA Margin % too high?
BioLASCO Taiwan Co's current EBITDA Margin % of 31.26% is 28% above median its 10-year median of 24.43. Over the past 10 years, this metric has ranged from a low of 21.76 to a high of 29.73. Based on the distribution chart, BioLASCO Taiwan Co ranks #133 out of 940 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioLASCO Taiwan Co has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioLASCO Taiwan Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioLASCO Taiwan Co ranks #133 out of 940 companies for EBITDA Margin %. This places BioLASCO Taiwan Co in the top 14% of its industry — outperforming the majority of peers. Historically, BioLASCO Taiwan Co's own EBITDA Margin % has ranged from 21.76 to 29.73 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on BioLASCO Taiwan Co and its competitors. BioLASCO Taiwan Co's current EBITDA Margin % is 31.26%, which is 28% above median its own 10-year median of 24.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLASCO Taiwan Co stock overvalued right now?
Based on GuruFocus' analysis, BioLASCO Taiwan Co (ROCO:6662) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$34.19, compared to a current price of NT$29.70 — trading 13.1% below its estimated fair value. The current EBITDA Margin % is 31.26%, which is 28% above median its 10-year median of 24.43. BioLASCO Taiwan Co's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For BioLASCO Taiwan Co (ROCO:6662), the current EBITDA Margin % is 31.26% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioLASCO Taiwan Co (ROCO:6662) Overvalued in 2026?
Based on GuruFocus' analysis, BioLASCO Taiwan Co stock appears to be undervalued.
The current stock price of NT$29.70 is trading 13.1% below its estimated GF Value™ of NT$34.19.
GuruFocus considers BioLASCO Taiwan Co to be Modestly Undervalued.
Key valuation signals for ROCO:6662:
EBITDA Margin %: 31.26% (28% above median its 10-year median of 24.43)
GF Value™: NT$34.19 vs. price of NT$29.70 (13.1% below fair value)
No single metric tells the full story. See the ROCO:6662 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioLASCO Taiwan Co Ltd is a biological experimental development company. The company has produced strains of laboratory rats and mice, including outbreed stocks, inbreed strains, and immunedeficient models. It offers reagent kits and equipment which include Allentown, a Biomedical data system, and PLAS LABS.
77GF Score
Get the complete analysis for ROCO:6662
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6662 has been successfully added to your 
